Thelansis’s “Diabetic Foot Ulcer (DFU) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.
Diabetic foot ulcer (DFU) is a serious complication of diabetes arising from the interaction of peripheral neuropathy, mechanical stress, peripheral arterial disease, infection, and impaired inflammatory and tissue-repair responses. These abnormalities can result in chronic, nonhealing wounds with substantial risks of infection, tissue loss, hospitalization, and lower-extremity amputation. Effective management centers on optimized wound care, debridement, pressure offloading, vascular assessment and revascularization when indicated, and appropriate treatment of clinically infected ulcers. Despite these measures, a subset of ulcers remains refractory or recurrent, creating an important unmet need for therapies that can address impaired angiogenesis, chronic inflammation, extracellular-matrix dysfunction, and defective re-epithelialization. Regenerative strategies—including cell therapies, placental-derived products, engineered biomaterials, extracellular vesicles, and growth-factor-based approaches—are being investigated to enhance tissue repair and perfusion. Recent clinical studies have reported encouraging findings for selected cell and tissue-derived therapies, but heterogeneous trial designs and limited long-term evidence continue to constrain broad adoption. For industry stakeholders, the key development opportunity lies in identifying regenerative approaches that provide reproducible, durable healing when optimized standard care alone is insufficient.
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
*Survey is customized based on client requirements
1. Key Findings and Analyst Commentary
2. Competitive Landscape
3. Product Attribute Analysis
4. Primary Market Research
5. Unmet Need and TPP Analysis
6. Regulatory and Reimbursement Environments (by country and payer insights)
7. Appendix (e.g., bibliography, methodology)
No snapshots available.
That depends on the file type you choose: the Excel epidemiology model, the Excel market forecast model with dashboard, and the full analyst report in PowerPoint with a PDF version.
Within 48 to 72 hours of purchase.
Yes. Choose EU5, G7 or G8, or pick individual markets in the panel.
Yes. Request a free sample to preview the scope and sample pages.
Yes. The forecast model is customizable, and our analysts can tailor the scope to your questions.
Yes. Inquire for bundle discounted pricing and we will send you exclusive pricing for the reports you need.
Choose the file type you want to purchase or request.
No file type found.
Select markets to include.
No markets match your search.
Not sure which report fits your question? Our team will point you to the right one.
Tell us what you are looking for and we will tailor the research to your indication, markets and questions.
Prefer to talk it through? Email clientsupport@thelansis.com
You asked for for covering . We will reply to .
Fill in your details and our expert consultants will get in touch with you.
Get a sneak peek at the latest Diabetic Foot Ulcer (DFU) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026 report
Our team will get in touch with you shortly about the Diabetic Foot Ulcer (DFU) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026 report.